CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
Authors:
- Sanna HallamiesSHSanna Hallamies
- Liisa M. PelttariLPLiisa M. Pelttari
- Paula Poikonen-SakselaPPPaula Poikonen-Saksela
- Antti JekunenAJAntti Jekunen
- Arja Jukkola-VuorinenAJArja Jukkola-Vuorinen
- Päivi AuvinenPAPäivi Auvinen
- Carl BlomqvistCBCarl Blomqvist
- Kristiina AittomäkiKAKristiina Aittomäki
- Johanna MattsonJMJohanna Mattson
- Heli NevanlinnaHNHeli Nevanlinna
Open Access
- 5 September 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-5
Abstract
Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less well understood. In this study, we have genotyped 68 MBC patients for the known breast or ovarian cancer associated mutations in the Finnish population in CHEK2, PALB2, RAD51C, RAD51D, and FANCM genes. CHEK2 c.1100delC mutation was found in 4 patients (5.9%), which is significantly more frequent than in the control population (OR: 4.47, 95% CI 1.51–13.18, p = 0.019). Four CHEK2 I157T variants were also detected, but the frequency did not significantly differ from population controls (p = 0.781). No RAD51C, RAD51D, PALB2, or FANCM mutations were found. These data suggest that the CHEK2 c.1100delC mutation is associated with an increased risk for MBC in the Finnish population.Keywords
This publication has 33 references indexed in Scilit:
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerNew England Journal of Medicine, 2016
- Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia SubtypeCancer Discovery, 2015
- Breast-Cancer Risk in Families with Mutations in PALB2New England Journal of Medicine, 2014
- Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder PopulationPLOS Genetics, 2014
- A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1Journal of Medical Genetics, 2012
- RAD51C is a susceptibility gene for ovarian cancerHuman Molecular Genetics, 2011
- A recurrent mutation in PALB2 in Finnish cancer familiesNature, 2007
- Role of CHEK2*1100delC in unselected series of non‐BRCA1/2 male breast cancersInternational Journal of Cancer, 2003
- CHEK2 1100delC is not a risk factor for male breast cancer populationInternational Journal of Cancer, 2003
- A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast CancerThe American Journal of Human Genetics, 2002